Compounds > platensimycin
Page last updated: 2024-12-11

platensimycin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

platensimycin: has antidiabetic and antisteatotic activities; a pentacyclic ketolide (structurally similar to adamantane) connected by an amide bond to 3-amino-2,4-dihydroxybenzoic acid; inhibits cellular lipid biosynthesis; discovered while screening compounds from Streptomyces platensis bacteria in a South African soil sample with S. aureus bacteria deficient in FabF protein; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

platensimycin : A monocarboxylic acid amide obtained by the formal condensation of the amino group of 3-amino-2,4-dihydroxybenzoic acid with the carboxy group of the oxatetracyclic cage component. It is an antibiotic isolated from Streptomyces platensis and exhibits inhibitory activity against fatty acid synthase. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6857724
CHEMBL ID411278
CHEBI ID68236
MeSH IDM0498829

Synonyms (22)

Synonym
chebi:68236 ,
CHEMBL411278
PMN ,
platensimycin
(-)-platensimycin
DB08407
NCGC00183212-01
unii-q3dq78kofy
q3dq78kofy ,
835876-32-9
benzoic acid, 3-((3-((1s,3s,4s,5as,9s,9ar)-1,4,5,8,9,9a-hexahydro-3,9-dimethyl-8-oxo-3h-1,4:3,5a-dimethano-2-benzoxepin-9-yl)-1-oxopropyl)amino)-2,4-dihydroxy-
C20132
3-({3-[(1s,4as,6s,7s,9s,9ar)-1,6-dimethyl-2-oxo-1,2,5,6,7,8,9,9a-octahydro-6,9-epoxy-4a,7-methanobenzo[7]annulen-1-yl]propanoyl}amino)-2,4-dihydroxybenzoic acid
platensimycin [mi]
3-((3-((1s,3s,4s,5as,9s,9ar)-1,4,5,8,9,9a-hexahydro-3,9-dimethyl-8-oxo-3h-1,4:3,5a-dimethano-2-benzoxepin-9-yl)-1-oxopropyl)amino)-2,4-dihydroxybenzoic acid
platensimycin, (-)-
DTXSID80894888
Q423275
3-[3-[(1s,5s,6r,7s,9s,10s)-5,9-dimethyl-4-oxo-8-oxatetracyclo[7.2.1.17,10.01,6]tridec-2-en-5-yl]propanoylamino]-2,4-dihydroxybenzoic acid
CS-0093585
HY-127146
AKOS040754744

Research Excerpts

Overview

Platensimycin (PTM) is a potent FabB/FabF inhibitor, while its poor pharmacokinetics hampers the clinical development. It acts on bacterial fatty acid synthase and exhibits excellent antibacterial activity.

ExcerptReferenceRelevance
"Platensimycin (PTM) is a potent FabB/FabF inhibitor, while its poor pharmacokinetics hampers the clinical development."( Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
Deng, Y; Duan, Y; Huang, Y; Ji, X; Li, Y; Ren, N; Shen, B; Su, M; Wen, Z; Weng, X, 2019)		1.52
"Platensimycin is a natural product isolated from a soil streptomycete, which contains an adamantane-like moiety extensively modified from a diterpenoid precursor."( Synthesis and biological evaluation of platensic alcohol as an adamantane surrogate in antitumor drug lead adaphostin.
Duan, Y; Huang, Y; Wen, Z; Xiong, Y, 2021)		1.34
"Platensimycin (PTM) is a promising natural antibiotic lead that acts on bacterial fatty acid synthase and exhibits excellent antibacterial activity."( Platensimycin-berberine chloride co-amorphous drug system: Sustained release and prolonged half-life.
Bai, E; Chen, X; Duan, Y; Huang, Y; Li, D; Wang, Z; Zhang, H, 2022)		2.89
"Platensimycin (PL) is a new promising antibiotic whose biosynthetic production is costly."( Membrane Affinity of Platensimycin and Its Dialkylamine Analogs.
Cember, A; Guo, M; Rowe, I; Sintim, HO; Sukharev, S; Yasmann, A, 2015)		1.46
"Platensimycin (PTM) is a recently discovered broad-spectrum antibiotic produced by Streptomyces platensis. "( Antidiabetic and antisteatotic effects of the selective fatty acid synthase (FAS) inhibitor platensimycin in mouse models of diabetes.
Chung, CC; Ellsworth, KP; Karanam, BV; Lassman, ME; Lee, SH; Li, C; Miller, C; Myers, RW; Powles, M; Salituro, G; Singh, SB; Tota, MR; Wang, J; Wu, M; Zhang, BB, 2011)		2.03
"Platensimycin (1a) is a novel broad spectrum Gram-positive antibiotic produced by Streptomyces platensis."( Isolation, structure, and absolute stereochemistry of platensimycin, a broad spectrum antibiotic discovered using an antisense differential sensitivity strategy.
Ball, RG; Basilio, A; Diez, MT; Genilloud, O; Herath, KB; Jayasuriya, H; Ondeyka, JG; Pelaez, F; Singh, SB; Tsou, NN; Vicente, F; Wang, J; Young, K; Zhang, C; Zink, DL, 2006)		1.3
"Platensimycin is a natural product isolated from various strains of Streptomyces platensis which exhibits antimicrobial activity against Gram positive bacteria, including vancomycin- and linezolide-resistant species. "( Synthesis of platensimycin analogues and their antibiotic potency.
Bracher, F; Knorr, V; Krauss, J; Manhardt, V; Scheffels, S, 2008)		2.16

Actions

ExcerptReferenceRelevance
"Platensimycin (1) displays antibacterial activity due to its inhibition of the elongation condensing enzyme (FabF), a novel mode of action that could potentially lead to a breakthrough in developing a new generation of antibiotics. "( Synthesis and biological evaluation of platensimycin analogs.
Chen, X; Colletti, SL; Ding, FX; Dorso, K; Ha, SN; Hammond, ML; Kodali, S; Maccoss, M; Parthasarathy, G; Shen, HC; Singh, SB; Soisson, SM; Tata, JR; Wang, J, 2009)		2.06

Treatment

ExcerptReferenceRelevance
"Treatment with platensimycin eradicates Staphylococcus aureus infection in mice."( Platensimycin is a selective FabF inhibitor with potent antibiotic properties.
Allocco, J; Barrett, J; Bartizal, K; Basilio, A; Becker, JW; Colwell, L; Cully, D; Cummings, R; Dorso, K; Felcetto, T; Galgoci, A; Genilloud, O; Gill, C; Ha, S; Herath, K; Hermes, JD; Hernandez, L; Jayasuriya, H; Kodali, S; Lee, SH; Michael, B; Motyl, M; Ondeyka, J; Painter, R; Parthasarathy, G; Pelaez, F; Schmatz, D; Shoop, W; Silver, LL; Singh, SB; Soisson, SM; Tang, YS; Tormo, JR; Vicente, F; Wang, J; Young, K; Zhang, C, 2006)		2.12
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
antimicrobial agentA substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.
EC 2.3.1.85 (fatty acid synthase) inhibitorAn EC 2.3.1.* (acyltransferase transferring other than amino-acyl group) inhibitor that interferes with the action of fatty acid synthase (EC 2.3.1.85), a multi-enzyme protein involved in fatty acid synthesis.
antibacterial agentA substance (or active part thereof) that kills or slows the growth of bacteria.
bacterial metaboliteAny prokaryotic metabolite produced during a metabolic reaction in bacteria.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (6)

ClassDescription
dihydroxybenzoic acidAny member of the class of hydroxybenzoic acids carrying two phenolic hydroxy groups on the benzene ring and its derivatives.
polycyclic cageA polycyclic compound having the shape of a cage.
cyclic etherAny ether in which the oxygen atom forms part of a ring.
cyclic ketone
aromatic amideAn amide in which the amide linkage is bonded directly to an aromatic system.
monocarboxylic acid amideA carboxamide derived from a monocarboxylic acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (142)

Assay IDTitleYearJournalArticle
AID1563601Inhibition of FabB/FabF in methicillin-resistant Staphylococcus aureus 3074 clinical isolate assessed as antibacterial activity after 16 hrs by agar dilution method2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID1430502Drug level in C57Bl/6 mouse plasma treated with platensimycin D1 at 10 mg/kg, iv administered as single dose measured after 60 mins by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1430499Drug level in C57Bl/6 mouse urine at 10 mg/kg, iv administered as single dose measured after 60 mins by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1550810Antibacterial activity against Streptococcus pneumoniae
AID1563634Inhibition of FabB/FabF in methicillin-resistant Staphylococcus aureus 2962 clinical isolate assessed as antibacterial activity after 16 hrs by agar dilution method2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID1563633Inhibition of FabB/FabF in methicillin-sensitive Staphylococcus aureus 2955 clinical isolate assessed as antibacterial activity after 16 hrs by agar dilution method2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID1563620Inhibition of FabB/FabF in methicillin-resistant Staphylococcus aureus 3140 clinical isolate assessed as antibacterial activity after 16 hrs by agar dilution method2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID1350030Antibacterial activity against methicillin-sensitive Staphylococcus aureus isolate 1 incubated overnight by agar dilution method2018Journal of natural products, 02-23, Volume: 81, Issue:2
Biomimetic Stereoselective Sulfa-Michael Addition Leads to Platensimycin and Platencin Sulfur Analogues against Methicillin-Resistant Staphylococcus aureus.
AID1563631Inhibition of FabB/FabF in methicillin-sensitive Staphylococcus aureus 2952 clinical isolate assessed as antibacterial activity after 16 hrs by agar dilution method2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID1350034Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate 5 incubated overnight by agar dilution method2018Journal of natural products, 02-23, Volume: 81, Issue:2
Biomimetic Stereoselective Sulfa-Michael Addition Leads to Platensimycin and Platencin Sulfur Analogues against Methicillin-Resistant Staphylococcus aureus.
AID1563611Inhibition of FabB/FabF in methicillin-resistant Staphylococcus aureus 3103 clinical isolate assessed as antibacterial activity after 16 hrs by agar dilution method2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID1563603Inhibition of FabB/FabF in methicillin-resistant Staphylococcus aureus 3082 clinical isolate assessed as antibacterial activity after 16 hrs by agar dilution method2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID1563606Inhibition of FabB/FabF in methicillin-resistant Staphylococcus aureus 3093 clinical isolate assessed as antibacterial activity after 16 hrs by agar dilution method2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID1430511Antibacterial activity against Staphylococcus aureus ATCC 25923 after 18 hrs by broth dilution method2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1430476Volume of distribution in C57Bl/6 mouse at 3 mg/kg, iv administered as single dose by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1430496Ratio of drug level in C57Bl/6 mouse adipose tissue to plasma at 10 mg/kg, iv administered as single dose measured after 60 mins by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1744573Binding affinity to His6-tagged Escherichia coli FabF C163Q mutant expressed in Escherichia coli BL21 (DE3) assessed as change in enthalpy measured after 200 sec by isothermal titration calorimetry2021ACS medicinal chemistry letters, Mar-11, Volume: 12, Issue:3
Semisynthesis and Biological Evaluation of Platencin Thioether Derivatives: Dual FabF and FabH Inhibitors against MRSA.
AID1563636Antibacterial activity against methicillin-resistant Staphylococcus aureus infected in C57BL/6J mouse model of peritonitis assessed as mouse survival at 10 mg/kg, ip dosed at 1 hr and 5 hrs post infection and measured for 7 days relative to control2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID1563614Inhibition of FabB/FabF in methicillin-resistant Staphylococcus aureus 3108 clinical isolate assessed as antibacterial activity after 16 hrs by agar dilution method2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID1563621Inhibition of FabB/FabF in methicillin-resistant Staphylococcus aureus 3150 clinical isolate assessed as antibacterial activity after 16 hrs by agar dilution method2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID1430512Antibacterial activity against Micrococcus luteus ATCC 9431 after 18 hrs by broth dilution method2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1563613Inhibition of FabB/FabF in methicillin-resistant Staphylococcus aureus 3105 clinical isolate assessed as antibacterial activity after 16 hrs by agar dilution method2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID1430493Ratio of drug level in C57Bl/6 mouse lung to plasma at 10 mg/kg, iv administered as single dose measured after 60 mins by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1563604Inhibition of FabB/FabF in methicillin-resistant Staphylococcus aureus 3086 clinical isolate assessed as antibacterial activity after 16 hrs by agar dilution method2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID1412974Antibacterial activity against Staphylococcus aureus ATCC 29213 after 16 hrs by agar dilution method2018MedChemComm, May-01, Volume: 9, Issue:5
The semi-synthesis, biological evaluation and docking analysis of the oxime, hydrazine and hydrazide derivatives of platensimycin.
AID1744574Binding affinity to His6-tagged Escherichia coli FabF C163Q mutant expressed in Escherichia coli BL21 (DE3) assessed as change in entropy measured after 200 sec by isothermal titration calorimetry2021ACS medicinal chemistry letters, Mar-11, Volume: 12, Issue:3
Semisynthesis and Biological Evaluation of Platencin Thioether Derivatives: Dual FabF and FabH Inhibitors against MRSA.
AID1430513In vivo stability in C57Bl/6 mouse lung assessed as compound hydrolysis at 10 mg/kg, iv administered as single dose measured after 60 mins by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1550808Antibacterial activity against Staphylococcus aureus
AID1350033Antibacterial activity against methicillin-sensitive Staphylococcus aureus isolate 4 incubated overnight by agar dilution method2018Journal of natural products, 02-23, Volume: 81, Issue:2
Biomimetic Stereoselective Sulfa-Michael Addition Leads to Platensimycin and Platencin Sulfur Analogues against Methicillin-Resistant Staphylococcus aureus.
AID1744565Inhibition of Staphylococcus aureus FabH A81V/A111T mutant assessed as bacterial growth inhibition measured after 18 hrs by resazurin dye based broth dilution assay2021ACS medicinal chemistry letters, Mar-11, Volume: 12, Issue:3
Semisynthesis and Biological Evaluation of Platencin Thioether Derivatives: Dual FabF and FabH Inhibitors against MRSA.
AID1430490Drug uptake in C57Bl/6 mouse muscle at 10 mg/kg, iv administered as single dose measured after 60 mins by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1430495Ratio of drug level in C57Bl/6 mouse muscle to plasma at 10 mg/kg, iv administered as single dose measured after 60 mins by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1430518In vivo stability in C57Bl/6 mouse kidney assessed as compound hydrolysis by measuring platensic acid level at 10 mg/kg, iv administered as single dose measured after 60 mins by LC-MS/MS analysis relative to platensimycin2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1434675Anti-bacterial activity against methicillin-susceptible Staphylococcus aureus CCARM 0027 by 2-fold microtiter broth dilution method2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Cadiolides J-M, antibacterial polyphenyl butenolides from the Korean tunicate Pseudodistoma antinboja.
AID1744564Antibacterial activity against methicillin resistant Staphylococcus aureus assessed as inhibition of bacterial growth measured after 16 hrs by agar plate dilution method2021ACS medicinal chemistry letters, Mar-11, Volume: 12, Issue:3
Semisynthesis and Biological Evaluation of Platencin Thioether Derivatives: Dual FabF and FabH Inhibitors against MRSA.
AID1744572Binding affinity to His6-tagged Escherichia coli FabF C163Q mutant expressed in Escherichia coli BL21 (DE3) assessed as stoichiometry ratio measured after 200 sec by isothermal titration calorimetry2021ACS medicinal chemistry letters, Mar-11, Volume: 12, Issue:3
Semisynthesis and Biological Evaluation of Platencin Thioether Derivatives: Dual FabF and FabH Inhibitors against MRSA.
AID1563619Inhibition of FabB/FabF in methicillin-resistant Staphylococcus aureus 3116 clinical isolate assessed as antibacterial activity after 16 hrs by agar dilution method2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID1563605Inhibition of FabB/FabF in methicillin-resistant Staphylococcus aureus 3090 clinical isolate assessed as antibacterial activity after 16 hrs by agar dilution method2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID1563632Inhibition of FabB/FabF in methicillin-sensitive Staphylococcus aureus 2954 clinical isolate assessed as antibacterial activity after 16 hrs by agar dilution method2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID1430460Elimination half life in C57Bl/6 mouse at 3 mg/kg, iv administered as single dose by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1563609Inhibition of FabB/FabF in methicillin-resistant Staphylococcus aureus 3097 clinical isolate assessed as antibacterial activity after 16 hrs by agar dilution method2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID1430505Drug metabolism in mouse hepatic microsomes assessed as amide hydrolysis-mediated platensic acid formation at 1 uM up to 60 mins in presence of NADPH by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1563582Inhibition of FabB/FabF in methicillin-resistant Staphylococcus aureus assessed as antibacterial activity at 5 ug/disk after 18 hrs by agar disk diffusion method2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID1430504Intrinsic clearance in mouse hepatic microsomes at 1 uM up to 60 mins by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1563610Inhibition of FabB/FabF in methicillin-resistant Staphylococcus aureus 3100 clinical isolate assessed as antibacterial activity after 16 hrs by agar dilution method2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID1430471AUC (0 to 8 hrs) in C57Bl/6 mouse at 10 mg/kg, po administered as single dose via gavage by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1412976Antibacterial activity against methicillin-resistant Staphylococcus aureus after 16 hrs by agar dilution method2018MedChemComm, May-01, Volume: 9, Issue:5
The semi-synthesis, biological evaluation and docking analysis of the oxime, hydrazine and hydrazide derivatives of platensimycin.
AID1563595Inhibition of FabB/FabF in methicillin-resistant Staphylococcus aureus 2984 clinical isolate assessed as antibacterial activity after 16 hrs by agar dilution method2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID1563630Inhibition of FabB/FabF in methicillin-resistant Staphylococcus aureus 3196 clinical isolate assessed as antibacterial activity after 16 hrs by agar dilution method2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID1350038Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate 9 incubated overnight by agar dilution method2018Journal of natural products, 02-23, Volume: 81, Issue:2
Biomimetic Stereoselective Sulfa-Michael Addition Leads to Platensimycin and Platencin Sulfur Analogues against Methicillin-Resistant Staphylococcus aureus.
AID1324787Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 measured after 18 hrs by broth dilution method2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Antibacterial sulfur-containing platensimycin and platencin congeners from Streptomyces platensis SB12029.
AID1563590Inhibition of FabB/FabF in methicillin-resistant Staphylococcus aureus 2959 clinical isolate assessed as antibacterial activity after 16 hrs by agar dilution method2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID1563593Inhibition of FabB/FabF in methicillin-resistant Staphylococcus aureus 2978 clinical isolate assessed as antibacterial activity after 16 hrs by agar dilution method2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID1430488Drug uptake in C57Bl/6 mouse lung at 10 mg/kg, iv administered as single dose measured after 60 mins by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1744555Antibacterial activity against Enterococcus faecalis ATCC 29212 assessed as inhibition of bacterial growth measured after 16 hrs by agar plate dilution method2021ACS medicinal chemistry letters, Mar-11, Volume: 12, Issue:3
Semisynthesis and Biological Evaluation of Platencin Thioether Derivatives: Dual FabF and FabH Inhibitors against MRSA.
AID1744571Binding affinity to His6-tagged Escherichia coli FabF C163Q mutant expressed in Escherichia coli BL21 (DE3) assessed as binding constant measured after 200 sec by isothermal titration calorimetry2021ACS medicinal chemistry letters, Mar-11, Volume: 12, Issue:3
Semisynthesis and Biological Evaluation of Platencin Thioether Derivatives: Dual FabF and FabH Inhibitors against MRSA.
AID1350029Antibacterial activity against Staphylococcus aureus ATCC 29213 incubated overnight by agar dilution method2018Journal of natural products, 02-23, Volume: 81, Issue:2
Biomimetic Stereoselective Sulfa-Michael Addition Leads to Platensimycin and Platencin Sulfur Analogues against Methicillin-Resistant Staphylococcus aureus.
AID1563626Inhibition of FabB/FabF in methicillin-resistant Staphylococcus aureus 3181 clinical isolate assessed as antibacterial activity after 16 hrs by agar dilution method2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID1350036Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate 7 incubated overnight by agar dilution method2018Journal of natural products, 02-23, Volume: 81, Issue:2
Biomimetic Stereoselective Sulfa-Michael Addition Leads to Platensimycin and Platencin Sulfur Analogues against Methicillin-Resistant Staphylococcus aureus.
AID1563635Inhibition of FabB/FabF in methicillin-sensitive Staphylococcus aureus 2956 clinical isolate assessed as antibacterial activity after 16 hrs by agar dilution method2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID1430515In vivo stability in C57Bl/6 mouse adipose tissue assessed as compound hydrolysis at 10 mg/kg, iv administered as single dose measured after 60 mins by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1350031Antibacterial activity against methicillin-sensitive Staphylococcus aureus isolate 2 incubated overnight by agar dilution method2018Journal of natural products, 02-23, Volume: 81, Issue:2
Biomimetic Stereoselective Sulfa-Michael Addition Leads to Platensimycin and Platencin Sulfur Analogues against Methicillin-Resistant Staphylococcus aureus.
AID1430524In vivo stability in C57Bl/6 mouse brain assessed as compound hydrolysis at 10 mg/kg, iv administered as single dose measured after 60 mins by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1434678Anti-bacterial activity against methicillin-susceptible Staphylococcus aureus CCARM 3640 by 2-fold microtiter broth dilution method2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Cadiolides J-M, antibacterial polyphenyl butenolides from the Korean tunicate Pseudodistoma antinboja.
AID1744562Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as inhibition of bacterial growth measured after 16 hrs by agar plate dilution method2021ACS medicinal chemistry letters, Mar-11, Volume: 12, Issue:3
Semisynthesis and Biological Evaluation of Platencin Thioether Derivatives: Dual FabF and FabH Inhibitors against MRSA.
AID1430475Observed clearance in C57Bl/6 mouse at 3 mg/kg, iv administered as single dose by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1434677Anti-bacterial activity against methicillin-susceptible Staphylococcus aureus CCARM 0205 by 2-fold microtiter broth dilution method2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Cadiolides J-M, antibacterial polyphenyl butenolides from the Korean tunicate Pseudodistoma antinboja.
AID1430516In vivo stability in C57Bl/6 mouse plasma assessed as compound hydrolysis by measuring platensic acid level at 10 mg/kg, iv administered as single dose measured after 60 mins by LC-MS/MS analysis relative to platensimycin2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1430486Drug uptake in C57Bl/6 mouse plasma at 10 mg/kg, iv administered as single dose measured after 60 mins by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1430466Cmax in C57Bl/6 mouse at 10 mg/kg, po administered as single dose via gavage by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1563599Inhibition of FabB/FabF in methicillin-resistant Staphylococcus aureus 3065 clinical isolate assessed as antibacterial activity after 16 hrs by agar dilution method2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID1430485Plasma concentration in C57Bl/6 mouse at 3 mg/kg, iv administered as single dose measured after 2 hrs by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1430483Oral bioavailability in C57Bl/6 mouse at 10 mg/kg administered as single dose via gavage by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1563624Inhibition of FabB/FabF in methicillin-resistant Staphylococcus aureus 3161 clinical isolate assessed as antibacterial activity after 16 hrs by agar dilution method2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID1563615Inhibition of FabB/FabF in methicillin-resistant Staphylococcus aureus 3110 clinical isolate assessed as antibacterial activity after 16 hrs by agar dilution method2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID1744563Antibacterial activity against methicillin sensitive Staphylococcus aureus assessed as inhibition of bacterial growth measured after 16 hrs by agar plate dilution method2021ACS medicinal chemistry letters, Mar-11, Volume: 12, Issue:3
Semisynthesis and Biological Evaluation of Platencin Thioether Derivatives: Dual FabF and FabH Inhibitors against MRSA.
AID1430506Drug metabolism in mouse hepatic microsomes assessed as amide hydrolysis-mediated platensic acid formation at 1 uM up to 60 mins in absence of NADPH by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1550809Antibacterial activity against Enterococcus faecium
AID1563627Inhibition of FabB/FabF in methicillin-resistant Staphylococcus aureus 3182 clinical isolate assessed as antibacterial activity after 16 hrs by agar dilution method2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID1563586Inhibition of FabB/FabF in methicillin-resistant Staphylococcus aureus assessed as antibacterial activity after 16 hrs by agar dilution method2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID1563589Inhibition of FabB/FabF in methicillin-resistant Staphylococcus aureus 2957 clinical isolate assessed as antibacterial activity after 16 hrs by agar dilution method2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID1434679Anti-bacterial activity against methicillin-resistant Staphylococcus aureus CCARM 3089 by 2-fold microtiter broth dilution method2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Cadiolides J-M, antibacterial polyphenyl butenolides from the Korean tunicate Pseudodistoma antinboja.
AID1563594Inhibition of FabB/FabF in methicillin-resistant Staphylococcus aureus 2980 clinical isolate assessed as antibacterial activity after 16 hrs by agar dilution method2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID1768533Antibacterial activity against methicillin-resistant Staphylococcus aureus2021Bioorganic & medicinal chemistry letters, 09-15, Volume: 48Synthesis and biological evaluation of platensic alcohol as an adamantane surrogate in antitumor drug lead adaphostin.
AID1563592Inhibition of FabB/FabF in methicillin-resistant Staphylococcus aureus 2976 clinical isolate assessed as antibacterial activity after 16 hrs by agar dilution method2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID1350032Antibacterial activity against methicillin-sensitive Staphylococcus aureus isolate 3 incubated overnight by agar dilution method2018Journal of natural products, 02-23, Volume: 81, Issue:2
Biomimetic Stereoselective Sulfa-Michael Addition Leads to Platensimycin and Platencin Sulfur Analogues against Methicillin-Resistant Staphylococcus aureus.
AID1744575Binding affinity to His6-tagged Escherichia coli FabF C163Q mutant expressed in Escherichia coli BL21 (DE3) assessed Gibbs free energy change measured after 200 sec by isothermal titration calorimetry2021ACS medicinal chemistry letters, Mar-11, Volume: 12, Issue:3
Semisynthesis and Biological Evaluation of Platencin Thioether Derivatives: Dual FabF and FabH Inhibitors against MRSA.
AID1430498Apparent permeability by PAMPA2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1412975Antibacterial activity against methicillin-sensitive Staphylococcus aureus after 16 hrs by agar dilution method2018MedChemComm, May-01, Volume: 9, Issue:5
The semi-synthesis, biological evaluation and docking analysis of the oxime, hydrazine and hydrazide derivatives of platensimycin.
AID1434682Anti-bacterial activity against methicillin-resistant Staphylococcus aureus CCARM 3635 by 2-fold microtiter broth dilution method2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Cadiolides J-M, antibacterial polyphenyl butenolides from the Korean tunicate Pseudodistoma antinboja.
AID1430514In vivo stability in C57Bl/6 mouse muscle assessed as compound hydrolysis at 10 mg/kg, iv administered as single dose measured after 60 mins by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1430487Drug uptake in C57Bl/6 mouse liver at 10 mg/kg, iv administered as single dose measured after 60 mins by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1430465Cmax in C57Bl/6 mouse at 3 mg/kg, iv administered as single dose by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1430497Drug uptake in C57Bl/6 mouse brain at 10 mg/kg, iv administered as single dose measured after 60 mins by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1430521In vivo stability in C57Bl/6 mouse liver assessed as compound hydrolysis at 10 mg/kg, iv administered as single dose measured after 60 mins by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1430470AUC (0 to 8 hrs) in C57Bl/6 mouse at 3 mg/kg, iv administered as single dose by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1744568Antibacterial activity against Escherichia coli harboring delta tolC mutant assessed as inhibition of bacterial growth measured after 16 hrs by agar plate dilution method2021ACS medicinal chemistry letters, Mar-11, Volume: 12, Issue:3
Semisynthesis and Biological Evaluation of Platencin Thioether Derivatives: Dual FabF and FabH Inhibitors against MRSA.
AID1434681Anti-bacterial activity against methicillin-resistant Staphylococcus aureus CCARM 3634 by 2-fold microtiter broth dilution method2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Cadiolides J-M, antibacterial polyphenyl butenolides from the Korean tunicate Pseudodistoma antinboja.
AID1563597Inhibition of FabB/FabF in methicillin-resistant Staphylococcus aureus 3046 clinical isolate assessed as antibacterial activity after 16 hrs by agar dilution method2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID1430523In vivo stability in C57Bl/6 mouse urine assessed as compound hydrolysis at 10 mg/kg, iv administered as single dose measured after 60 mins by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1563607Inhibition of FabB/FabF in methicillin-resistant Staphylococcus aureus 3094 clinical isolate assessed as antibacterial activity after 16 hrs by agar dilution method2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID1563602Inhibition of FabB/FabF in methicillin-resistant Staphylococcus aureus 3079 clinical isolate assessed as antibacterial activity after 16 hrs by agar dilution method2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID1434676Anti-bacterial activity against methicillin-susceptible Staphylococcus aureus CCARM 0204 by 2-fold microtiter broth dilution method2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Cadiolides J-M, antibacterial polyphenyl butenolides from the Korean tunicate Pseudodistoma antinboja.
AID1563596Inhibition of FabB/FabF in methicillin-resistant Staphylococcus aureus 2985 clinical isolate assessed as antibacterial activity after 16 hrs by agar dilution method2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID1430461Elimination half life in C57Bl/6 mouse at 10 mg/kg, po administered as single dose via gavage by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1563622Inhibition of FabB/FabF in methicillin-resistant Staphylococcus aureus 3156 clinical isolate assessed as antibacterial activity after 16 hrs by agar dilution method2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID1350028Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate 11 incubated overnight by agar dilution method2018Journal of natural products, 02-23, Volume: 81, Issue:2
Biomimetic Stereoselective Sulfa-Michael Addition Leads to Platensimycin and Platencin Sulfur Analogues against Methicillin-Resistant Staphylococcus aureus.
AID1563591Inhibition of FabB/FabF in methicillin-resistant Staphylococcus aureus 2968 clinical isolate assessed as antibacterial activity after 16 hrs by agar dilution method2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID1744566Inhibition of Staphylococcus aureus FabH A81V mutant assessed as bacterial growth inhibition measured after 18 hrs by resazurin dye based broth dilution assay2021ACS medicinal chemistry letters, Mar-11, Volume: 12, Issue:3
Semisynthesis and Biological Evaluation of Platencin Thioether Derivatives: Dual FabF and FabH Inhibitors against MRSA.
AID1563588Inhibition of FabB/FabF in methicillin-resistant Staphylococcus aureus 2953 clinical isolate assessed as antibacterial activity after 16 hrs by agar dilution method2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID1430520In vivo stability in C57Bl/6 mouse plasma assessed as compound hydrolysis at 10 mg/kg, iv administered as single dose measured after 60 mins by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1563587Inhibition of FabB/FabF in methicillin-resistant Staphylococcus aureus 2951 clinical isolate assessed as antibacterial activity after 16 hrs by agar dilution method2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID1350037Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate 8 incubated overnight by agar dilution method2018Journal of natural products, 02-23, Volume: 81, Issue:2
Biomimetic Stereoselective Sulfa-Michael Addition Leads to Platensimycin and Platencin Sulfur Analogues against Methicillin-Resistant Staphylococcus aureus.
AID1563628Inhibition of FabB/FabF in methicillin-resistant Staphylococcus aureus 3188 clinical isolate assessed as antibacterial activity after 16 hrs by agar dilution method2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID1434680Anti-bacterial activity against methicillin-resistant Staphylococcus aureus CCARM 3090 by 2-fold microtiter broth dilution method2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Cadiolides J-M, antibacterial polyphenyl butenolides from the Korean tunicate Pseudodistoma antinboja.
AID1563625Inhibition of FabB/FabF in methicillin-resistant Staphylococcus aureus 3163 clinical isolate assessed as antibacterial activity after 16 hrs by agar dilution method2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID1563585Inhibition of FabB/FabF in methicillin-sensitive Staphylococcus aureus assessed as antibacterial activity after 16 hrs by agar dilution method2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID1324788Antibacterial activity against Micrococcus luteus ATCC 9431 measured after 18 hrs by broth dilution method2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Antibacterial sulfur-containing platensimycin and platencin congeners from Streptomyces platensis SB12029.
AID1563608Inhibition of FabB/FabF in methicillin-resistant Staphylococcus aureus 3095 clinical isolate assessed as antibacterial activity after 16 hrs by agar dilution method2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID1430517In vivo stability in C57Bl/6 mouse liver assessed as compound hydrolysis by measuring platensic acid level at 10 mg/kg, iv administered as single dose measured after 60 mins by LC-MS/MS analysis relative to platensimycin2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1563612Inhibition of FabB/FabF in methicillin-resistant Staphylococcus aureus 3104 clinical isolate assessed as antibacterial activity after 16 hrs by agar dilution method2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID1430500Ratio of drug level in C57Bl/6 mouse urine to plasma at 10 mg/kg, iv administered as single dose measured after 60 mins by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1563629Inhibition of FabB/FabF in methicillin-resistant Staphylococcus aureus 3193 clinical isolate assessed as antibacterial activity after 16 hrs by agar dilution method2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID1563584Inhibition of FabB/FabF in Staphylococcus aureus ATCC 29213 assessed as antibacterial activity after 16 hrs by agar dilution method2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID1563616Inhibition of FabB/FabF in methicillin-resistant Staphylococcus aureus 3111 clinical isolate assessed as antibacterial activity after 16 hrs by agar dilution method2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID1350039Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate 10 incubated overnight by agar dilution method2018Journal of natural products, 02-23, Volume: 81, Issue:2
Biomimetic Stereoselective Sulfa-Michael Addition Leads to Platensimycin and Platencin Sulfur Analogues against Methicillin-Resistant Staphylococcus aureus.
AID1430491Drug uptake in C57Bl/6 mouse adipose tissue at 10 mg/kg, iv administered as single dose measured after 60 mins by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1430492Ratio of drug level in C57Bl/6 mouse liver to plasma at 10 mg/kg, iv administered as single dose measured after 60 mins by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1563598Inhibition of FabB/FabF in methicillin-resistant Staphylococcus aureus 3056 clinical isolate assessed as antibacterial activity after 16 hrs by agar dilution method2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID1563623Inhibition of FabB/FabF in methicillin-resistant Staphylococcus aureus 3158 clinical isolate assessed as antibacterial activity after 16 hrs by agar dilution method2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID1430510Drug metabolism in mouse hepatic microsomes assessed as glucuronidation of carboxylic acid at 1 uM up to 60 mins in absence of NADPH by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1350035Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate 6 incubated overnight by agar dilution method2018Journal of natural products, 02-23, Volume: 81, Issue:2
Biomimetic Stereoselective Sulfa-Michael Addition Leads to Platensimycin and Platencin Sulfur Analogues against Methicillin-Resistant Staphylococcus aureus.
AID1430494Ratio of drug level in C57Bl/6 mouse kidney to plasma at 10 mg/kg, iv administered as single dose measured after 60 mins by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1563618Inhibition of FabB/FabF in methicillin-resistant Staphylococcus aureus 3114 clinical isolate assessed as antibacterial activity after 16 hrs by agar dilution method2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID1430509Drug metabolism in mouse hepatic microsomes assessed as hydroxylation at 1 uM up to 60 mins in absence of NADPH by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1430484Plasma concentration in C57Bl/6 mouse at 3 mg/kg, iv administered as single dose measured after 5 mins by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1430489Drug uptake in C57Bl/6 mouse kidney at 10 mg/kg, iv administered as single dose measured after 60 mins by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1563600Inhibition of FabB/FabF in methicillin-resistant Staphylococcus aureus 3071 clinical isolate assessed as antibacterial activity after 16 hrs by agar dilution method2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID1563617Inhibition of FabB/FabF in methicillin-resistant Staphylococcus aureus 3112 clinical isolate assessed as antibacterial activity after 16 hrs by agar dilution method2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.
AID1430522In vivo stability in C57Bl/6 mouse kidney assessed as compound hydrolysis at 10 mg/kg, iv administered as single dose measured after 60 mins by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1430519In vivo stability in C57Bl/6 mouse urine assessed as compound hydrolysis by measuring platensic acid level at 10 mg/kg, iv administered as single dose measured after 60 mins by LC-MS/MS analysis relative to platensimycin2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
In vivo instability of platensimycin and platencin: Synthesis and biological evaluation of urea- and carbamate-platensimycin.
AID1744567Antibacterial activity against methicillin resistant Staphylococcus aureus assessed as inhibition of bacterial growth measured after 18 hrs in presence of 10% human serum by resazurin dye based broth dilution assay2021ACS medicinal chemistry letters, Mar-11, Volume: 12, Issue:3
Semisynthesis and Biological Evaluation of Platencin Thioether Derivatives: Dual FabF and FabH Inhibitors against MRSA.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (112)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's45 (40.18)29.6817
2010's58 (51.79)24.3611
2020's9 (8.04)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.50 (24.57)
Research Supply Index4.73 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index39.34 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (29.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews16 (14.29%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other96 (85.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
carbamates
[no description available]		2.1510amino-acid anion
methane
Methane: The simplest saturated hydrocarbon. It is a colorless, flammable gas, slightly soluble in water. It is one of the chief constituents of natural gas and is formed in the decomposition of organic matter. (Grant & Hackh's Chemical Dictionary, 5th ed). methane : A one-carbon compound in which the carbon is attached by single bonds to four hydrogen atoms. It is a colourless, odourless, non-toxic but flammable gas (b.p. -161degreeC).		3.5620alkane;
gas molecular entity;
mononuclear parent hydride;
one-carbon compound		bacterial metabolite;
fossil fuel;
greenhouse gas
chlorine
chloride : A halide anion formed when chlorine picks up an electron to form an an anion.		2.4110halide anion;
monoatomic chlorine		cofactor;
Escherichia coli metabolite;
human metabolite
iodine
Iodine: A nonmetallic element of the halogen group that is represented by the atomic symbol I, atomic number 53, and atomic weight of 126.90. It is a nutritionally essential element, especially important in thyroid hormone synthesis. In solution, it has anti-infective properties and is used topically.. diiodine : Molecule comprising two covalently bonded iodine atoms with overall zero charge..		2.0610diatomic iodinenutrient
urea
pseudourea: clinical use; structure. isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.		7.1510isourea;
monocarboxylic acid amide;
one-carbon compound		Daphnia magna metabolite;
Escherichia coli metabolite;
fertilizer;
flour treatment agent;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
tyrphostin ag957
tyrphostin AG957: tyrosine kinase blocker; structure given in first source		2.3110aromatic amine
berberine
[no description available]		7.4110alkaloid antibiotic;
berberine alkaloid;
botanical anti-fungal agent;
organic heteropentacyclic compound		antilipemic drug;
antineoplastic agent;
antioxidant;
EC 1.1.1.141 [15-hydroxyprostaglandin dehydrogenase (NAD(+))] inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.13.11.52 (indoleamine 2,3-dioxygenase) inhibitor;
EC 1.21.3.3 (reticuline oxidase) inhibitor;
EC 2.1.1.116 [3'-hydroxy-N-methyl-(S)-coclaurine 4'-O-methyltransferase] inhibitor;
EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor;
EC 2.7.11.10 (IkappaB kinase) inhibitor;
EC 3.1.1.4 (phospholipase A2) inhibitor;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor;
EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
geroprotector;
hypoglycemic agent;
metabolite;
potassium channel blocker
ether
Ether: A mobile, very volatile, highly flammable liquid used as an inhalation anesthetic and as a solvent for waxes, fats, oils, perfumes, alkaloids, and gums. It is mildly irritating to skin and mucous membranes.. ether : An organooxygen compound with formula ROR, where R is not hydrogen.. diethyl ether : An ether in which the oxygen atom is linked to two ethyl groups.		7.1310ether;
volatile organic compound		inhalation anaesthetic;
non-polar solvent;
refrigerant
propidium
Propidium: Quaternary ammonium analog of ethidium; an intercalating dye with a specific affinity to certain forms of DNA and, used as diiodide, to separate them in density gradients; also forms fluorescent complexes with cholinesterase which it inhibits.		2.4110phenanthridines;
quaternary ammonium ion		fluorochrome;
intercalator
sulfamethoxazole
Sulfamethoxazole: A bacteriostatic antibacterial agent that interferes with folic acid synthesis in susceptible bacteria. Its broad spectrum of activity has been limited by the development of resistance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p208). sulfamethoxazole : An isoxazole (1,2-oxazole) compound having a methyl substituent at the 5-position and a 4-aminobenzenesulfonamido group at the 3-position.		2.1510isoxazoles;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antibacterial agent;
antiinfective agent;
antimicrobial agent;
drug allergen;
EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
epitope;
P450 inhibitor;
xenobiotic
sulfasalazine
Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907). sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.		7.4110
triclosan
[no description available]		2.1510aromatic ether;
dichlorobenzene;
monochlorobenzenes;
phenols		antibacterial agent;
antimalarial;
drug allergen;
EC 1.3.1.9 [enoyl-[acyl-carrier-protein] reductase (NADH)] inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
fungicide;
persistent organic pollutant;
xenobiotic
aspartic acid
Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.. aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent. L-aspartic acid : The L-enantiomer of aspartic acid.		2.1510aspartate family amino acid;
aspartic acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
mouse metabolite;
neurotransmitter
carbostyril
Quinolones: A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID.. quinolin-2(1H)-one : A quinolone that is 1,2-dihydroquinoline substituted by an oxo group at position 2.		3.1710monohydroxyquinoline;
quinolone		bacterial xenobiotic metabolite
methicillin
Methicillin: One of the PENICILLINS which is resistant to PENICILLINASE but susceptible to a penicillin-binding protein. It is inactivated by gastric acid so administered by injection.. methicillin : A penicillin that is 6-aminopenicillanic acid in which one of the amino hydrogens is replaced by a 2,6-dimethoxybenzoyl group.		2.0510penicillin allergen;
penicillin		antibacterial drug
ampicillin
Ampicillin: Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic.. ampicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-phenylacetamido group.		2.3110beta-lactam antibiotic;
penicillin allergen;
penicillin		antibacterial drug
carvone
carvone: an oxidized derivative of limonene; RN given refers to cpd without isomeric designation; L-carvone has spearmint flavor, D-carvone has dill/caraway flavor. carvone : A p-menthane monoterpenoid that consists of cyclohex-2-enone having methyl and isopropenyl substituents at positions 2 and 5, respectively.		2.0410botanical anti-fungal agent;
carvones		allergen
furan
furan : A monocyclic heteroarene with a structure consisting of a 5-membered ring containing four carbons and one oxygen, with formula C4H4O. It is a toxic, flammable, low-boiling (31degreeC) colourless liquid.		7.0610furans;
mancude organic heteromonocyclic parent;
monocyclic heteroarene		carcinogenic agent;
hepatotoxic agent;
Maillard reaction product
thiophenes
Thiophenes: A monocyclic heteroarene furan in which the oxygen atom is replaced by a sulfur.. thiophenes : Compounds containing at least one thiophene ring.		2.0410mancude organic heteromonocyclic parent;
monocyclic heteroarene;
thiophenes;
volatile organic compound		non-polar solvent
piperonal
piperonal: has been used as a pediculicide; structure. piperonal : An arenecarbaldehyde that is 1,3-benzodioxole substituted by a formyl substituent at position 5. It has been isolated from Piper nigrum.		2.0410arenecarbaldehyde;
benzodioxoles		fragrance;
insect repellent;
plant metabolite
adamantane
Adamantane: A tricyclo bridged hydrocarbon.		9.551060adamantanes;
polycyclic alkane
thiazoles
[no description available]		3.31101,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
2-piperidone
2-piperidone: structure given in first source. piperidin-2-one : A delta-lactam that is piperidine which is substituted by an oxo group at position 2.		3.3110delta-lactam;
piperidones		EC 1.2.1.88 (L-glutamate gamma-semialdehyde dehydrogenase) inhibitor
vancomycin
Vancomycin: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.. vancomycin : A complex glycopeptide from Streptomyces orientalis. It inhibits a specific step in the synthesis of the peptidoglycan layer in the Gram-positive bacteria Staphylococcus aureus and Clostridium difficile.		2.1510glycopeptideantibacterial drug;
antimicrobial agent;
bacterial metabolite
rhodium
Rhodium: A hard and rare metal of the platinum group, atomic number 45, atomic weight 102.905, symbol Rh.. rhodium atom : A cobalt group element atom of atomic number 45.		7.7430cobalt group element atom
samarium
Samarium: An element of the rare earth family of metals. It has the atomic symbol Sm, atomic number 62, and atomic weight 150.36. The oxide is used in the control rods of some nuclear reactors.		2.0310f-block element atom;
lanthanoid atom
silver
Silver: An element with the atomic symbol Ag, atomic number 47, and atomic weight 107.87. It is a soft metal that is used medically in surgical instruments, dental prostheses, and alloys. Long-continued use of silver salts can lead to a form of poisoning known as ARGYRIA.		2.0310copper group element atom;
elemental silver		Escherichia coli metabolite
chromium
Chromium: A trace element that plays a role in glucose metabolism. It has the atomic symbol Cr, atomic number 24, and atomic weight 52. According to the Fourth Annual Report on Carcinogens (NTP85-002,1985), chromium and some of its compounds have been listed as known carcinogens.. chromium ion : An chromium atom having a net electric charge.. chromium atom : A chromium group element atom that has atomic number 24.		7.4620chromium group element atom;
metal allergen		micronutrient
iodine
[no description available]		2.0310halide anion;
monoatomic iodine		human metabolite
phenyl acetate
phenyl acetate: The ester formed between phenol and acetic acid. Don't confuse with phenylacetic acid derivatives listed under PHENYLACETATES.. phenyl acetate : An acetate ester obtained by the formal condensation of phenol with acetic acid.		2.0410benzenes;
phenyl acetates
alkenes
[no description available]		2.4520
oxazolidin-2-one
Oxazolidinones: Derivatives of oxazolidin-2-one. They represent an important class of synthetic antibiotic agents.. oxazolidin-2-one : An oxazolidinone that is 1,3-oxazolidine with an oxo substituent at position 2.. oxazolidinone : An oxazolidine containing one or more oxo groups.		2.0310carbamate ester;
oxazolidinone		metabolite
lumisantonin
lumisantonin: RN given refers to (3aR-(3aalpha,3bbeta,5abeta,6beta,8aalpha,8bR*))-isomer		2.1310
carbene
carbene: electrically neutral species H2C: and its derivatives, in which the carbon is covalently bonded to two univalent groups of any kind or a divalent group and bears two nonbonding electrons; carbene is the name of the parent hydride :CH2 ; hence, the name dichlorocarbene for :CCl2. However, names for acyclic and cyclic hydrocarbons containing one or more divalent carbon atoms are derived from the name of the corresponding all-4-hydrocarbon using the suffix -ylidene; methylene carbene also available. carbene : The electrically neutral species H2C(2.) and its derivatives, in which the carbon is covalently bonded to two univalent groups of any kind or a divalent group and bears two nonbonding electrons, which may be spin-paired (singlet state) or spin-non-paired (triplet state).		8.5620carbene;
methanediyl
sperm motility inhibitor 2
[no description available]		2.0310
hydroxyl radical
Hydroxyl Radical: The univalent radical OH. Hydroxyl radical is a potent oxidizing agent.		2.0510oxygen hydride;
oxygen radical;
reactive oxygen species
santonin
Santonin: Anthelmintic isolated from the dried unexpanded flower heads of Artemisia maritima and other species of Artemisia found principally in Russian and Chinese Turkestan and the Southern Ural region. (From Merck, 11th ed.)		2.1310botanical anti-fungal agent;
santonin		plant metabolite
nsc 680410
NSC 680410: a bcr/abl kinase inhibitor; structure in first source		2.3110
linezolid
[no description available]		3.3960acetamides;
morpholines;
organofluorine compound;
oxazolidinone		antibacterial drug;
protein synthesis inhibitor
mupirocin
Mupirocin: A topically used antibiotic from a strain of Pseudomonas fluorescens. It has shown excellent activity against gram-positive staphylococci and streptococci. The antibiotic is used primarily for the treatment of primary and secondary skin disorders, nasal infections, and wound healing.. mupirocin : An alpha,beta-unsaturated ester resulting from the formal condensation of the alcoholic hydroxy group of 9-hydroxynonanoic acid with the carboxy group of (2E)-4-[(2S)-tetrahydro-2H-pyran-2-yl]-3-methylbut-2-enoic acid in which the tetrahydropyranyl ring is substituted at positions 3 and 4 by hydroxy groups and at position 5 by a {(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl}methyl group. Originally isolated from the Gram-negative bacterium Pseudomonas fluorescens, it is used as a topical antibiotic for the treatment of Gram-positive bacterial infections.		2.2110alpha,beta-unsaturated carboxylic ester;
epoxide;
monocarboxylic acid;
oxanes;
secondary alcohol;
triol		antibacterial drug;
bacterial metabolite;
protein synthesis inhibitor
geranylgeranyl pyrophosphate
geranylgeranyl pyrophosphate: RN given refers to (E,E,E)-isomer. geranylgeranyl diphosphate : A polyprenol diphosphate having geranylgeranyl as the polyprenyl component.. 2-trans,6-trans,10-trans-geranylgeranyl diphosphate : The all-trans-isomer of geranylgeranyl diphosphate.		2.0710geranylgeranyl diphosphatemouse metabolite
kaurenoic acid
kaurenoic acid: isolated from leaves of Montanoa tomentosa; structure given in first source. ent-kaur-16-en-19-oic acid : An ent-kaurane diterpenoid that is ent-kauran-19-oic acid in which a double bond is present at position 16(17); exhibits anticancer and anti-HIV 1 activity.		2.610
cerulenin
Cerulenin: An epoxydodecadienamide isolated from several species, including ACREMONIUM, Acrocylindrum, and Helicoceras. It inhibits the biosynthesis of several lipids by interfering with enzyme function.. cerulenin : An epoxydodecadienamide isolated from several species, including Acremonium, Acrocylindrum and Helicoceras. It inhibits the biosynthesis of several lipids by interfering with enzyme function.		2.4820epoxide;
monocarboxylic acid amide		antifungal agent;
antiinfective agent;
antilipemic drug;
antimetabolite;
antimicrobial agent;
fatty acid synthesis inhibitor
bismuth
Bismuth: A metallic element that has the atomic symbol Bi, and atomic number 83. Its principal isotope is Bismuth 209.		7.0510metal atom;
pnictogen
sulfur
Sulfur: An element that is a member of the chalcogen family. It has an atomic symbol S, atomic number 16, and atomic weight [32.059; 32.076]. It is found in the amino acids cysteine and methionine.		2.8530chalcogen;
nonmetal atom		macronutrient
sinomenine
sinomenine: isolated from root of Sinomenium acutum; antirheumatic, antineuralgic		7.4110morphinane alkaloid
chlorhexidine
Chlorhexidine: A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.. chlorhexidine : A bisbiguanide compound with a structure consisting of two (p-chlorophenyl)guanide units linked by a hexamethylene bridge.		2.0310biguanides;
monochlorobenzenes		antibacterial agent;
antiinfective agent
dc 107
leinamycin: a thiazole containing macrolide characterized by an unusual 1,3-dioxo-1,2-dithiolane moiety that is spiro fused to an 18 member macrolactam ring; isolated from Streptomyces; MF C22-H26-N2-O6-S3; possible DNA alkylator; the leinamycin biosynthetic gene cluster from Streptomyces atroolivaceus S-140 consists of two polyketide synthases genes		3.3110dithiolanes
polymyxin b(1)
[no description available]		2.3110
isomigrastatin
isomigrastatin: isolated from Streptomyces platensis; structure in first source		3.3110macrolide
ly-146032
[no description available]		2.1510heterodetic cyclic peptide;
lipopeptide antibiotic;
lipopeptide;
macrocycle;
macrolide		antibacterial drug;
bacterial metabolite;
calcium-dependent antibiotics
platencin
platencin: inhibits both FabF and FabH; structure in first source. platencin : A monocarboxylic acid amide obtained by the formal condensation of the amino group of 3-amino-2,4-dihydroxybenzoic acid with the carboxy group of the polycyclic cage component. It is an antibiotic isolated from Streptomyces platensis and exhibits inhibitory activity against fatty acid synthase.		7.82350aromatic amide;
cyclic ketone;
dihydroxybenzoic acid;
monocarboxylic acid amide;
polycyclic cage		antibacterial agent;
antimicrobial agent;
bacterial metabolite;
EC 2.3.1.85 (fatty acid synthase) inhibitor
salicylates
Salicylates: The salts or esters of salicylic acids, or salicylate esters of an organic acid. Some of these have analgesic, antipyretic, and anti-inflammatory activities by inhibiting prostaglandin synthesis.. hydroxybenzoate : Any benzoate derivative carrying a single carboxylate group and at least one hydroxy substituent.. salicylates : Any salt or ester arising from reaction of the carboxy group of salicylic acid, or any ester resulting from the condensation of the phenolic hydroxy group of salicylic acid with an organic acid.. salicylate : A monohydroxybenzoate that is the conjugate base of salicylic acid.		2.1110monohydroxybenzoateplant metabolite
thiolactomycin
thiolactomycin: from actinomycetes; structure given in first source		2.0410
ConditionIndicatedRelationship StrengthStudiesTrials
Primary Peritonitis
[description not available]		02.8930
Infections, Staphylococcal
[description not available]		02.7930
Peritonitis
INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs.		02.8930
Staphylococcal Infections
Infections with bacteria of the genus STAPHYLOCOCCUS.		02.7930
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		03.0740
Infection, Wound
[description not available]		02.3110
Infections, Staphylococcal Skin
[description not available]		02.6620
Staphylococcal Skin Infections
Infections to the skin caused by bacteria of the genus STAPHYLOCOCCUS.		02.6620
Phlegmon
[description not available]		02.4110
Infectious Skin Diseases
[description not available]		02.4110
Cellulitis
An acute, diffuse, and suppurative inflammation of loose connective tissue, particularly the deep subcutaneous tissues, and sometimes muscle, which is most commonly seen as a result of infection of a wound, ulcer, or other skin lesions.		02.4110
Skin Diseases, Infectious
Skin diseases caused by bacteria, fungi, parasites, or viruses.		02.4110
Infections, Chlamydia
[description not available]		02.1510
Chlamydia Infections
Infections with bacteria of the genus CHLAMYDIA.		02.1510
Burns
Injuries to tissues caused by contact with heat, steam, chemicals (BURNS, CHEMICAL), electricity (BURNS, ELECTRIC), or the like.		02.2110
Infectious Diseases
[description not available]		03.0610
Communicable Diseases
An illness caused by an infectious agent or its toxins that occurs through the direct or indirect transmission of the infectious agent or its products from an infected individual or via an animal, vector or the inanimate environment to a susceptible animal or human host.		03.0610
Bacterial Infections, Gram-Positive
[description not available]		03.3820
Gram-Positive Bacterial Infections
Infections caused by bacteria that retain the crystal violet stain (positive) when treated by the gram-staining method.		03.3820
Liver Steatosis
[description not available]		02.0610
Diabetes Mellitus
A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.		02.0610
Fatty Liver
Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.		02.0610
Health Care Associated Infection
[description not available]		02.0310
Cross Infection
Any infection which a patient contracts in a health-care institution.		02.0310